The company focuses on oncology, onco-hematology, severe infectious diseases, specialty treatments, immunology and inflammation, and orphan and rare diseases. They have long-standing partnerships with leading global players in the pharmaceutical field and embrace Open Innovation to drive strong R&D productivity. With a team of more than 600 professionals, they offer an unparalleled infrastructure among their peers and aim to enhance lives and restore hopes to patients with severe and debilitating conditions.